Valuation: Bolt Biotherapeutics, Inc.

Market Cap 6.86M 5.98M 5.63M 5.13M 9.62M 657M 9.63M 67.44M 25.99M 335M 25.76M 25.19M 1.08B P/E 2026 *
-0.15x
P/E 2027 * -0.18x
Enterprise Value 6.86M 5.98M 5.63M 5.13M 9.62M 657M 9.63M 67.44M 25.99M 335M 25.76M 25.19M 1.08B EV / Sales 2026 *
34.3x
EV / Sales 2027 * 1.96x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+1.97%
1 week-8.79%
Current month-8.79%
1 month-0.95%
3 months-9.48%
6 months-17.12%
Current year-33.61%
1 week 3.1
Extreme 3.1
4.36
1 month 3.1
Extreme 3.1
4.36
Current year 3.1
Extreme 3.1
7.2
1 year 3.1
Extreme 3.1
7.2
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
299.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Free

Chairman

5,000 0.2602%
28/1/26 Free

Chief Operating Officer

10,000 0.5210%
28/1/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%-8.79%-32.02%-83.35% 6.86M
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+0.02%+37.52%+83.28% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+1.18%-2.66%-15.90%+363.06% 26.21B
+2.01%-0.86%-0.72%-7.91% 24.13B
0.00%+6.81%+24.48%-11.44% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-2.13%+1.63%+44.33%+164.71% 14.46B
-5.15%-8.41%-11.68%+821.86% 14.24B
Average +0.51%+0.77%+29.04%+177.99% 27.52B
Weighted average by Cap. +1.45%+2.90%+36.93%+151.74%

Financials

2026 *2027 *
Net sales 200K 174K 164K 150K 280K 19.16M 281K 1.97M 758K 9.76M 751K 735K 31.5M 3.5M 3.05M 2.87M 2.62M 4.91M 335M 4.91M 34.42M 13.27M 171M 13.15M 12.86M 551M
Net income -47.4M -41.33M -38.92M -35.45M -66.46M -4.54B -66.54M -466M -180M -2.31B -178M -174M -7.46B -47.5M -41.42M -39.01M -35.52M -66.6M -4.55B -66.69M -467M -180M -2.32B -178M -174M -7.48B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
22/09/26 USD 3.630 +1.97% 19,512
18/09/26 USD 3.560 +6.43% 249,406
17/09/26 USD 3.345 -7.85% 90,467
16/09/26 USD 3.630 -9.93% 29,004
15/09/26 USD 4.030 +1.26% 45,827
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.560USD
Average target price
29.00USD
Spread / Average Target
+714.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!